$MYGN
MYRIAD GENETICS INC

2017 Q1 Form 10-Q Financial Statement

#000156459017008267 Filed on May 03, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q2 2016 Q1
Revenue $196.9M $186.4M $190.5M
YoY Change 3.36% -1.84% 5.83%
Cost Of Revenue $37.90M $40.00M $33.60M
YoY Change 12.8% 4.17% 1.82%
Gross Profit $159.0M $146.4M $156.9M
YoY Change 1.34% -3.37% 6.73%
Gross Profit Margin 80.75% 78.54% 82.36%
Selling, General & Admin $122.1M $91.30M $90.50M
YoY Change 34.92% -5.49% -0.88%
% of Gross Profit 76.79% 62.36% 57.68%
Research & Development $17.60M $19.50M $17.20M
YoY Change 2.33% 4.28% 2.99%
% of Gross Profit 11.07% 13.32% 10.96%
Depreciation & Amortization $3.700M $6.700M $3.500M
YoY Change 5.71% 1.52% 6.06%
% of Gross Profit 2.33% 4.58% 2.23%
Operating Expenses $139.7M $110.8M $107.7M
YoY Change 29.71% -3.9% -0.28%
Operating Profit $5.500M $35.60M $42.60M
YoY Change -87.09% -1.66% 19.33%
Interest Expense $1.500M $400.0K $300.0K
YoY Change 400.0% 300.0% 200.0%
% of Operating Profit 27.27% 1.12% 0.7%
Other Income/Expense, Net $300.0K $1.200M $500.0K
YoY Change -40.0% -250.0% -350.0%
Pretax Income $5.800M $37.20M $43.10M
YoY Change -86.54% 4.79% 21.41%
Income Tax $3.000M $1.500M $10.50M
% Of Pretax Income 51.72% 4.03% 24.36%
Net Earnings $2.800M $35.70M $32.60M
YoY Change -91.41% 90.91% 52.34%
Net Earnings / Revenue 1.42% 19.15% 17.11%
Basic Earnings Per Share $0.04 $0.46
Diluted Earnings Per Share $0.04 $482.4K $0.44
COMMON SHARES
Basic Shares Outstanding 68.10M 70.30M shares 70.90M shares
Diluted Shares Outstanding 68.30M 73.50M shares

Balance Sheet

Concept 2017 Q1 2016 Q2 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $172.1M $159.0M $216.7M
YoY Change -20.58% 9.81% 61.24%
Cash & Equivalents $123.8M $68.50M $120.5M
Short-Term Investments $48.30M $90.50M $96.20M
Other Short-Term Assets $9.600M $22.20M $36.40M
YoY Change -73.63% -14.62% 54.89%
Inventory $47.40M $38.30M $25.30M
Prepaid Expenses
Receivables $114.8M $91.70M $91.10M
Other Receivables $4.400M $3.300M $2.900M
Total Short-Term Assets $348.3M $314.5M $372.4M
YoY Change -6.47% 10.9% 31.86%
LONG-TERM ASSETS
Property, Plant & Equipment $53.00M $58.30M $60.00M
YoY Change -11.67% -13.24% -13.17%
Goodwill $315.0M $195.3M $177.9M
YoY Change 77.07% 10.21% -3.96%
Intangibles $498.1M $227.5M $183.2M
YoY Change 171.89% 18.12% -6.38%
Long-Term Investments $53.40M $79.90M $69.70M
YoY Change -23.39% 96.8% 69.17%
Other Assets $5.000M $5.000M
YoY Change 0.0% 0.0%
Total Long-Term Assets $919.5M $566.0M $495.8M
YoY Change 85.46% 17.28% -0.17%
TOTAL ASSETS
Total Short-Term Assets $348.3M $314.5M $372.4M
Total Long-Term Assets $919.5M $566.0M $495.8M
Total Assets $1.268B $880.5M $868.2M
YoY Change 46.03% 14.92% 11.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $26.80M $21.10M $13.80M
YoY Change 94.2% 0.0% -23.14%
Accrued Expenses $49.30M $49.50M $50.80M
YoY Change -2.95% 7.38% 6.1%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $221.7M $72.30M $66.10M
YoY Change 235.4% 5.24% -1.6%
LONG-TERM LIABILITIES
Long-Term Debt $167.1M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $21.50M $7.800M $2.000M
YoY Change 975.0% 100.0% -68.85%
Total Long-Term Liabilities $21.50M $7.800M $2.000M
YoY Change 975.0% 100.0% -68.85%
TOTAL LIABILITIES
Total Short-Term Liabilities $221.7M $72.30M $66.10M
Total Long-Term Liabilities $21.50M $7.800M $2.000M
Total Liabilities $519.9M $132.4M $98.00M
YoY Change 430.51% 27.19% -11.03%
SHAREHOLDERS EQUITY
Retained Earnings -$81.40M -$73.20M -$69.20M
YoY Change 17.63% -4.94% 11.11%
Common Stock $840.2M $830.8M $847.7M
YoY Change -0.88% 11.35% 121000.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $748.2M $739.6M $770.2M
YoY Change
Total Liabilities & Shareholders Equity $1.268B $880.5M $868.2M
YoY Change 46.03% 14.92% 11.44%

Cashflow Statement

Concept 2017 Q1 2016 Q2 2016 Q1
OPERATING ACTIVITIES
Net Income $2.800M $35.70M $32.60M
YoY Change -91.41% 90.91% 52.34%
Depreciation, Depletion And Amortization $3.700M $6.700M $3.500M
YoY Change 5.71% 1.52% 6.06%
Cash From Operating Activities $41.10M $38.50M $45.90M
YoY Change -10.46% -24.51% 53.51%
INVESTING ACTIVITIES
Capital Expenditures -$1.500M -$2.200M -$700.0K
YoY Change 114.29% 10.0% -84.44%
Acquisitions
YoY Change
Other Investing Activities $11.00M -$41.60M -$15.40M
YoY Change -171.43% 5100.0% -152.56%
Cash From Investing Activities $9.500M -$43.80M -$16.10M
YoY Change -159.01% 1464.29% -164.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -36.70M -46.30M -44.00M
YoY Change -16.59% 15.17% -21.43%
NET CHANGE
Cash From Operating Activities 41.10M 38.50M 45.90M
Cash From Investing Activities 9.500M -43.80M -16.10M
Cash From Financing Activities -36.70M -46.30M -44.00M
Net Change In Cash 13.90M -51.60M -14.20M
YoY Change -197.89% -745.0% 1083.33%
FREE CASH FLOW
Cash From Operating Activities $41.10M $38.50M $45.90M
Capital Expenditures -$1.500M -$2.200M -$700.0K
Free Cash Flow $42.60M $40.70M $46.60M
YoY Change -8.58% -23.21% 35.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5000000
CY2017Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
84700000
CY2017Q1 us-gaap Liabilities
Liabilities
519900000
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6800000
CY2016Q1 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
177400000
CY2016Q1 us-gaap Revenues
Revenues
190500000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
20000000
us-gaap Investment Income Interest
InvestmentIncomeInterest
500000
us-gaap Interest Expense
InterestExpense
4800000
us-gaap Interest Expense
InterestExpense
200000
CY2017Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
5200000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
2000000
CY2017Q1 us-gaap Liabilities Current
LiabilitiesCurrent
221700000
CY2016Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
17900000
CY2016Q2 mygn Prepaid Expense Excluding Prepaid Taxes Current
PrepaidExpenseExcludingPrepaidTaxesCurrent
18400000
CY2017Q1 mygn Prepaid Expense Excluding Prepaid Taxes Current
PrepaidExpenseExcludingPrepaidTaxesCurrent
9500000
CY2017Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
498100000
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-9500000
CY2016Q2 us-gaap Prepaid Taxes
PrepaidTaxes
3800000
CY2017Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
24900000
CY2017Q1 us-gaap Inventory Net
InventoryNet
47400000
CY2017Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
68118450
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
123800000
CY2016Q2 us-gaap Liabilities
Liabilities
132400000
CY2017Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
48300000
CY2016Q2 us-gaap Inventory Net
InventoryNet
38300000
CY2016Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
91700000
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68500000
CY2017Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
14300000
CY2017Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53000000
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
90500000
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
700000
CY2017Q1 us-gaap Prepaid Taxes
PrepaidTaxes
100000
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
830100000
CY2017Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
53400000
CY2017Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4400000
CY2017Q1 us-gaap Assets Current
AssetsCurrent
348300000
CY2017Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2700000
CY2017Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
114800000
CY2017Q1 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
7200000
CY2017Q1 us-gaap Long Term Debt
LongTermDebt
167100000
CY2017Q1 us-gaap Goodwill
Goodwill
315000000
CY2016Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
748100000
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
880500000
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1700000
mygn Cost Of Pharmaceutical And Clinical Services
CostOfPharmaceuticalAndClinicalServices
18700000
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
36700000
us-gaap Costs And Expenses
CostsAndExpenses
436200000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2400000
us-gaap Operating Income Loss
OperatingIncomeLoss
131200000
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
748100000
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73200000
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
534200000
us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
532000000
CY2017Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
11700000
CY2016Q1 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
13100000
us-gaap Operating Income Loss
OperatingIncomeLoss
32400000
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
42600000
CY2017Q1 us-gaap Common Stock Value
CommonStockValue
700000
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
839500000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10600000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-81400000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
748200000
CY2017Q1 us-gaap Minority Interest
MinorityInterest
-300000
CY2017Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
747900000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1267800000
CY2017Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
8100000
CY2017Q1 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
185200000
CY2017Q1 us-gaap Revenues
Revenues
196900000
CY2017Q1 us-gaap Cost Of Revenue
CostOfRevenue
37900000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
267800000
us-gaap Costs And Expenses
CostsAndExpenses
538500000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
300000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
300000
us-gaap Investment Income Interest
InvestmentIncomeInterest
900000
CY2017Q1 us-gaap Interest Expense
InterestExpense
1500000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1500000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
200000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4900000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
500000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
8000000
CY2016Q1 us-gaap Profit Loss
ProfitLoss
34500000
CY2017Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2016Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6900000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-600000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
35000000
mygn Non Cash Interest Expense
NonCashInterestExpense
400000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
200000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
400000
us-gaap Share Based Compensation
ShareBasedCompensation
22700000
us-gaap Share Based Compensation
ShareBasedCompensation
23900000
us-gaap Costmethod Investments Other Than Temporary Impairment
CostmethodInvestmentsOtherThanTemporaryImpairment
2400000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
27300000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
23500000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1300000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-2000000
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-31500000
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
900000
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
-2400000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-10900000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
8700000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
40300000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
28700000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3200000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1000000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6500000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
200000
us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
-3600000
us-gaap Increase Decrease In Prepaid Taxes
IncreaseDecreaseInPrepaidTaxes
27700000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2000000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2900000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1000000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
69600000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
127800000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
5400000
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
2800000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
216100000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
2600000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
74600000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
131400000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
142900000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
86600000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-150600000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-47600000
mygn Proceeds From Repayments Of Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromRepaymentsOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1300000
mygn Proceeds From Repayments Of Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromRepaymentsOfIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
85900000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
204000000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
199000000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
200000000
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
600000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
31600000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
107900000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
135100000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-22000000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
1200000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-1800000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
55300000
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
37000000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
56400000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
120500000
us-gaap Basis Of Accounting
BasisOfAccounting
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td> <td valign="top"> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">BASIS OF PRESENTATION</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the &#8220;Company&#8221; or &#8220;Myriad&#8221;) in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.&nbsp;&nbsp;All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2016, included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended June 30, 2016. Operating results for the three and nine months ended March 31, 2017 may not necessarily be indicative of results to be expected for any other interim period or for the full year.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The consolidated financial statements include the accounts of the Company&#8217;s majority-owned subsidiary, Assurex Canada, Ltd. which is 85% owned by Assurex Health, Inc. (&#8220;Assurex), a wholly owned subsidiary of the Company, and 15% owned by the Centre for Addiction and Mental Health. Assurex Canada, Ltd. is a consolidated subsidiary of Assurex Health, Inc. The value of the non-controlling interest represents the portion of Assurex Canada, Ltd.&#8217;s profit or loss and net assets that is not held by Assurex Health, Inc. The Company attributes comprehensive income or loss of the subsidiary between the Company and the non-controlling interest based on the respective ownership interest.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">New Accounting Pronouncements</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued Accounting Standards Update 2016-02, Leases (&#8220;ASU 2016-02&#8221;). ASU 2016-02 amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. ASU 2016-02 will be effective beginning in the first quarter of 2019. Early adoption of ASU 2016-02 is permitted. ASU 2016-02 requires a modified retrospective transition approach for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. The Company&#8217;s management is currently evaluating the impact of adopting ASU 2016-02 on the Company&#8217;s consolidated financial statements.</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Financial Accounting Standards Board issued ASU No. 2014-09, "Revenue from Contracts with Customers."&nbsp;&nbsp;Under the new standard, revenue is recognized at the time a good or service is transferred to a customer for the amount of consideration received for that specific good or service.&nbsp;&nbsp; In July 2015, the FASB voted to defer the effective date by one year to December 15, 2017 for interim and annual reporting periods beginning after that date.&nbsp;&nbsp;Early adoption is permitted for interim and annual periods beginning after the original effective date of December 15, 2016. Companies may use either a full retrospective or a modified retrospective approach to adopt the standard. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements.</p></div>
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64100000
us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
97100000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
66600000
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.95
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.91
CY2017Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
196900000
CY2016Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
207400000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
582300000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
610000000
CY2017Q1 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
12900000
CY2016Q1 us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
31500000
us-gaap Business Acquisitions Pro Forma Income Loss From Continuing Operations Before Changes In Accounting And Extraordinary Items Net Of Tax
BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax
25300000
CY2017Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
4200000
CY2016Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
23600000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-9100000
CY2017Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.06
CY2016Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
0.33
us-gaap Business Acquisition Pro Forma Earnings Per Share Basic
BusinessAcquisitionProFormaEarningsPerShareBasic
-0.13
CY2017Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.06
CY2016Q1 us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
0.32
us-gaap Business Acquisition Pro Forma Earnings Per Share Diluted
BusinessAcquisitionProFormaEarningsPerShareDiluted
-0.13
CY2017Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
225600000
CY2016Q2 us-gaap Available For Sale Equity Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleEquitySecuritiesAccumulatedGrossUnrealizedGainBeforeTax
500000
CY2016Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
238900000
CY2016Q2 us-gaap Investments And Cash
InvestmentsAndCash
238400000
CY2016Q2 mygn Investments And Cash At Fair Value
InvestmentsAndCashAtFairValue
238900000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
48300000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
52000000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
1500000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
48300000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
51900000
CY2017Q1 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
1500000
CY2017Q1 us-gaap Land
Land
2200000
CY2017Q1 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
16300000
CY2017Q1 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
22000000
CY2017Q1 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
105800000
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
146300000
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
93300000
CY2017Q1 us-gaap Depreciation
Depreciation
3700000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
119700000
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
49300000
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
37300000
CY2017Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
3000000
CY2016Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
2800000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11700000
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9400000
CY2016Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1300000
CY2017Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
168100000
CY2017Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1000000
CY2017Q1 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
5900000
CY2016Q2 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
5900000
CY2017Q1 mygn Other Liabilities Noncurrent Other
OtherLiabilitiesNoncurrentOther
1300000
CY2016Q2 mygn Other Liabilities Noncurrent Other
OtherLiabilitiesNoncurrentOther
1900000
CY2017Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
21500000
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18200000
CY2017Q1 mygn Number Of Defined Benefit Pension Plans
NumberOfDefinedBenefitPensionPlans
2
CY2017Q1 us-gaap Defined Benefit Plan Fair Value Of Plan Assets
DefinedBenefitPlanFairValueOfPlanAssets
100000
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2017Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68100000
CY2016Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.200
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69100000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.631
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.226
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68900000
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68900000
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
600000
us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
4400000
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
1600000
us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
2900000
CY2016Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70400000
CY2016Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70400000
CY2017Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
200000
CY2016Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2600000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
400000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
3100000
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9200000
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
100000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7000000
CY2017Q1 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
160700000
CY2016Q1 mygn Amount Of Reduction In Common Stock As Result Of Stock Repurchases
AmountOfReductionInCommonStockAsResultOfStockRepurchases
11200000
mygn Amount Of Reduction In Common Stock As Result Of Stock Repurchases
AmountOfReductionInCommonStockAsResultOfStockRepurchases
14500000
mygn Amount Of Reduction In Common Stock As Result Of Stock Repurchases
AmountOfReductionInCommonStockAsResultOfStockRepurchases
26000000
CY2016Q1 mygn Amount Charged To Retained Earnings As Result Of Stock Repurchases
AmountChargedToRetainedEarningsAsResultOfStockRepurchases
33300000
mygn Amount Charged To Retained Earnings As Result Of Stock Repurchases
AmountChargedToRetainedEarningsAsResultOfStockRepurchases
17100000
mygn Amount Charged To Retained Earnings As Result Of Stock Repurchases
AmountChargedToRetainedEarningsAsResultOfStockRepurchases
81900000
CY2017Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.475
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
Options and restricted stock units granted to our non-employee directors vest in full upon the earlier of (i) one full year of service on the Board following date of grant or (ii) the date of the next annual meeting of stockholders.
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8200000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7500000
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.52
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
13.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
24.49
CY2017Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2200000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7500000
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7600000
CY2017Q1 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
-23500000
CY2016Q2 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
162400000
CY2016Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
10400000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
130000000
mygn Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchase Accounting Adjustments
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchaseAccountingAdjustments
500000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
1900000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Other Comprehensive Income
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
-300000
CY2017Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
142500000
mygn Percent Of Employee Contribution To Deferred Savings Plan
PercentOfEmployeeContributionToDeferredSavingsPlan
0.50
mygn Employers Contribution Not To Exceed Percentage Of Employees Compensation
EmployersContributionNotToExceedPercentageOfEmployeesCompensation
0.04
CY2017Q1 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
1800000
CY2016Q1 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
1400000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
4800000
us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
4100000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2017Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
12900000
CY2016Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
6600000
us-gaap Income Taxes Paid
IncomeTaxesPaid
8500000
us-gaap Income Taxes Paid
IncomeTaxesPaid
28500000
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
-500000
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
200000

Files In Submission

Name View Source Status
0001564590-17-008267-index-headers.html Edgar Link pending
0001564590-17-008267-index.html Edgar Link pending
0001564590-17-008267.txt Edgar Link pending
0001564590-17-008267-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
mygn-10q_20170331.htm Edgar Link pending
mygn-20170331.xml Edgar Link completed
mygn-20170331.xsd Edgar Link pending
mygn-20170331_cal.xml Edgar Link unprocessable
mygn-20170331_def.xml Edgar Link unprocessable
mygn-20170331_lab.xml Edgar Link unprocessable
mygn-20170331_pre.xml Edgar Link unprocessable
mygn-ex311_6.htm Edgar Link pending
mygn-ex312_7.htm Edgar Link pending
mygn-ex321_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending